e-learning
resources
Madrid 2019
Sunday, 29.09.2019
The world of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.
C. Hayton (Manchester, United Kingdom), F. Elsawy (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), P. Rivera-Ortega (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom)
Source:
International Congress 2019 – The world of idiopathic pulmonary fibrosis
Session:
The world of idiopathic pulmonary fibrosis
Session type:
Poster Discussion
Number:
1728
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Hayton (Manchester, United Kingdom), F. Elsawy (Manchester, United Kingdom), T. Garfoot (Manchester, United Kingdom), C. Leonard (Manchester, United Kingdom), P. Rivera-Ortega (Manchester, United Kingdom), J. Blaikley (Manchester, United Kingdom), N. Chaudhuri (Manchester, United Kingdom). Safety and tolerability of immunosuppression in non-IPF ILD: clinical experience from a tertiary ILD centre.. 1728
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018
Year: 2018
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Clinical experience with nintedanib for IPF in 3 UK tertiary referral centres
Source: International Congress 2016 – IPF treatment II
Year: 2016
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Safety and efficacy of sputum induction in COPD patients
Source: Annual Congress 2013 –Respiratory nursing care: assessment, interventions and education
Year: 2013
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical and functional effectiveness of roflumilast in severe COPD patients
Source: Annual Congress 2013 –Modern approach to various clinical settings
Year: 2013
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Acute exacerbation of ILD: an Indian tertiary centre experience
Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment
Year: 2018
Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety.
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019
Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study.
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
The outcome of patients with COPD admitted to UK hospitals with an exacerbation. Results from the RCP/BTS national COPD audit
Source: Annual Congress 2005 - COPD - acute exacerbations
Year: 2005
Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems
Year: 2017
Clinical and inflammatory characteristics of patients with COPD in primary care: an observational study
Source: International Congress 2017 – Markers of COPD progression
Year: 2017
The feasibility, efficacy and safety of a multidisciplinary care pathway for in-patient treatment of acute exacerbation of bronchiectasis
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Year: 2021
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept